Corporate story

Founded in 2005 as a result of interdisciplinary research at the Karolinska Institute in Stockholm, Sweden, Vironova has quickly established a following of global customers working in highly-regulated and quality-demanding industries such as vaccine development, the pharmaceutical industry and material science.

By combining expertise in electron microscopy, virology, mathematics and image analysis, Vironova has developed a unique offering of services, hardware and software products. Today it has GLP-certified cell and virus facilities in Sweden that include equipment for advanced electron microscopy, image analysis, nano-characterization and viral clearance testing.

Intellectual property

Vironova strives to protect all technology and products developed. Patent applications are submitted in all relevant markets for new technology and technology improvements.

The technology is protected by patents and patent applications for three complementing image analysis methods, and covers the most important application areas in biological quality control.

Corporate governance

Vironova has a culture of responsibility, drive and cost consciousness, which
allows the company to innovate and market products and services at a high level.

  • Management
  • Board

Mohammed Homman

CEO

Mr. Homman has a M.Sc. in Chemistry and B.Sc. in biology from Uppsala University in 1998. Mohammed has been the driving force behind the development of the virus analysis technique and VN-180. Mohammed has received several national and international awards in recognition of his entrepreneurship and innovative research achievements. In 2003 Mohammed was chosen as one of the “Leaders of Tomorrow” by the Academy of Achievement, USA.

Dr. Ida-Maria Sintorn

CTO

Ida-Maria is associate professor (docent) in computerized image processing at Uppsala University, holds a Ph.D. in image analysis from Swedish University of Agricultural Sciences as well as a M.Sc. in molecular biotechnology engineering from Uppsala University. Ida-Maria has a solid background in theoretical and applied image analysis and pattern recognition. Ida-Maria has worked at Vironova since 2007.

Ulf Danielsson

Sales and Marketing Director

Ulf holds a B.Sc. in chemistry. He brings more than 30 years’ experience of sales and marketing in the life sciences industry to Vironova. Prior to joining the company he has held positions as Sales Manager and Sales Director at Pharmadule, Pall Filtration and Pharmacia Biotech (Ge Healthcare Life Sciences). Ulf has worked at Vironova since 2016.

Dr. Josefina Nilsson

Director of BU, EM services

Josefina holds a Ph.D. in biophysics and structural biology from the Karolinska Institute and a M.Sc. in chemistry from Uppsala University. Josefina has unique expertise in structural analysis of viruses and nanoparticles, electron microscopy and its industrial applications, gained from the PhD program “Biotechnology with an industrial focus” and from her work at Vironova. Josefina has worked at Vironova since 2007.

Dr. Carina Pèrez

Director of BU, Biosafety

Carina holds a Ph.D. in Medical Science from the Karolinska Institute and a M.Sc. in molecular cell biology from Södertörn University in Stockholm. She has a solid academic background in immunology, virology and vaccinology. Her research with focus on HIV has given her experience and skills in biosecurity risk assessment and sterile working techniques. Carina has worked at Vironova since 2013.

Nina Ewerlöf

Director of BU, Instruments

Nina studied engineering physics, biotechnology and business economics at Uppsala University. Nina has a long experience of sales and customer services to a variety of industries but always with technology and software as common denominator. Nina’s speciality is production, delivery, and customer success. Nina has worked at Vironova since August 2016.

Göran Nilsson

Business Development Director

Göran holds a M.Sc. in Management of information from Chalmers University and a M.Sc. in Economics from the University of Gothenburg. Göran has worked as a management consultant in strategy and operations for McKinsey & Company where he served clients in multiple industries, including several global pharmaceutical companies. Göran has worked at Vironova since 2016.

Ulrika Ledmyr

HR Director

Ulrika holds a B.Sc. in Human Resources and Labour Law from Stockholm University and one year studies in Psychology at Stockholm University. Ulrika has a long experience as Head of HR in different companies such as the service industry, IT-sector, Academy, public services and law firm. Ulrika’s speciality is structure, processes and building an HR-platform. Ulrika has worked at Vironova since 2016.

Anders Milton

Chairman of the board

Born 1947. Chairman of the Board since 2008.
B.Sc., M.D., Ph.D. Milton is the president of ERNA, a member of the government appointed Catastrophe Commission and a consultant within the health care sector. Dr. Milton is also on the board of publicly traded Q-Med AB. Dr. Milton has a long history of elected positions as well as government appointed positions. He has previously been both CEO and Secretary General of the Swedish Medical Association, chairman of the Council of the World Medical Association, Chairman of the Swedish Red Cross and Chairman of the Swedish Confederation of Professional Associations (SACO), as well as Government appointed co-ordinator of psychiatric services in Sweden and government appointed chairman of a committee on HIV/AIDS.

Mohammed Homman

CEO

Mr. Homman has a M.Sc. in Chemistry and B.Sc. in biology from Uppsala University in 1998. Mohammed has been the driving force behind the development of the virus analysis technique and VN-180. Mohammed has received several national and international awards in recognition of his entrepreneurship and innovative research achievements. In 2003 Mohammed was chosen as one of the “Leaders of Tomorrow” by the Academy of Achievement, USA.

Ulf Säther

Member of the board

Born 1959. Member of the board since 2014.
M.Sc. from Stockholm School of Economics. Ulf has 25 years of experience in the pharmaceutical industry, mostly in international and global roles. Most recently 10 years as President Europe in AstraZeneca, based in Brussels, followed by the role as Global Marketing Director at the company headquarters in London. Earlier in his career he also held sales and marketing roles in the US. Board member in RISE (Research Institutes of Sweden), a government body with 2500 employees doing front line research in collaboration with industry, N-side, Leuwen Belgium, a consulting firm in mathematical analysis, Nobelux, a trade org to support trade between Sweden and Belux. Former member of the board at AB Blåklader (working wear) and Chairman in the AZ Germany Supervisory Board. Industrial Advisor at EQT.

Alf Sollevi

Member of the board

Born 1951. Member of the Board since 2014. Professor in anesthesiology and intensive care since 1999 at the Department of Clinical Science, Intervention and Technology at the Karolinska Institute. Dr. Sollevi received his medical degree in 1976 and became a licensed physician in 1978. He received his PhD in 1981. After two years as Associate Professor of Pharmacology, he became a docent in anesthesiology and intensive care in 1986. During a long period, from 1982 to 2008, has Dr. Sollevi lead a research group that conducted basic studies as well as clinical examinations regarding effects and clinical applicability of the endogenous substance adenosine.

Mats Persson

Member of the board

Born 1948. Member of the board since 2014.
M.Sc. from Stockholm School of Economics, MBA from University of Berkeley, California. Mats Persson has an extensive experience as CEO at several Swedish companies including AGA Gas, Thermiaverken, Candor and Interspiro, with a focus on implementing major organizational changes and increasing profitability. During 1996-2012 Mats Persson served as main shareholder in Neuman and Nydahl, offering qualified counselling, leadership development and recruitment at managerial level to leading companies in Sweden, including Incentive, Skanska, Swedbank, Boliden, Loomis, Nynäs and Pharmacia. Mats Persson has over 20 years of experience in board work, and is currently board member at Prolight Diagnostics, Newfour, QBNK (Aktietorget) and Vironova.

Peter Thurell

Deputy member

Born 1946. Deputy member since 2014.
Chairman and CEO of international pharmaceutical company Item Development since 1989, following a period of positions as controller / trouble shooter and/or president in several medium size subsidiaries of Swedish investment group Navigator.Trained in the Royal Swedish Navy (captain), at the University of Lund (law), the University of Stockholm (tax law), the Stockholm School of Economics (BSc in economics and business administration) and IMD in Lausanne (international executive program).

Maria Homman

Deputy member

Maria Homman holds a PhD in polymer technology and has been a manager within R&D at AkzoNobel (initially Casco Adhesives) for 10 years, with responsibility for the development of products from idea to market, as well as customer support. Dr. Maria Homman was previously Member of the Board (2006-2011) and Chairman of the Board (2006-2008).

Legal structure

The Vironova group consists of four companies:

  • Intelligent Virus Imaging Inc. (IVI Inc.) is a fully owned subsidiary in the USA used for certain patent rights.
  • Vironova Biosafety AB is a fully owned subsidiary.
  • NOW Electronics AB is a fully owned subsidiary.
  • JOS AB is a fully owned subsidiary.

Financial reports



See Vironovas financial reports by choosing year in the field above.


2015 Annual Report

2015 Audit Report

2014 Audit Report

2014 Annual Report

2013 Audit report

2013 Annual Report

2012 Annual Report

Share structure, March 30, 2017

Share holder No. of shares % of capital % of votes
Holmsvanen AB 9 513 332 33,85% 15,93%
Mhomman AB 5 411 110 19,25% 62,00%
Alf Sollevi 4 067 042 14,47% 6,81%
Flerie Invest AB 1 000 000 3,56% 1,67%
Dyneq AB 913 958 3,25% 1,53%
Sanderling Invest AB 670 000 2,38% 1,12%
Anders Milton 493 000 1,75% 0,83%
TK Buss 428 718 1,53% 0,72%
Kralle Invest AB 300 000 1,07% 0,50%
Ten largest shareholders 22 797 160 81,11% 91,11%
Others (368) 5 305 893 18,89% 8,89%
Total 28 103 053 100,00% 100,00%

Share capital in Vironova AB at March 31,2017 amounted to SEK 1,405,154.15 distributed among 3 511 713 class A shares and 28 103 083 class B shares, each with a quotient value of SEK 0.05. The total number of shares amounted to 28 103 083. Class A shares carry ten voting rights each, while class B shares carry one vote. All shares provide equal entitlement to participation in company and are freely transferable.Source: Euroclear AB